Evidence map›Paper›PMID 40738675›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome.

Chiaki Kubara, Takuro Kuriyama, Seiya Hirakawa, Taro Tochigi, Masayasu Hayashi, Yayoi Matsuo, Tetsuya Eto, Shuichi Taniguchi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chiaki KubaraDepartment of Hematology, Hamanomachi Hospital, Japan.
Takuro KuriyamaDepartment of Hematology, Hamanomachi Hospital, Japan.
Seiya HirakawaDepartment of Hematology, Hamanomachi Hospital, Japan.
Taro TochigiDepartment of Hematology, Hamanomachi Hospital, Japan.
Masayasu HayashiDepartment of Hematology, Hamanomachi Hospital, Japan.
Yayoi MatsuoDepartment of Hematology, Hamanomachi Hospital, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Japan.
Shuichi TaniguchiDepartment of Hematology, Hamanomachi Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FMS-like tyrosine kinase 3 (FLT3) mutations are observed in 30% of acute myeloid leukemia (AML) cases and indicate a poor prognosis. FLT3 inhibitors, such as gilteritinib, improve outcomes but may cause differentiation syndrome (DS) in approximately 3% of patients. We herein report a case of FLT3-tyrosine kinase domain-mutated AML treated with idarubicin and cytarabine, followed by a single dose of gilteritinib. The patient developed DS that required intubation. Initial steroid therapy was ineffective; however, steroid pulse therapy and additional idarubicin resolved the DS. This case shows that gilteritinib-induced DS can occur early and severely and requires prompt and aggressive management.

Indexed as

Aniline Compoundsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationPyrazinesCell DifferentiationCytarabineFemaleHumansIdarubicinMaleMiddle AgedProtein Kinase InhibitorsSyndromeAniline CompoundsCytarabineFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibIdarubicinProtein Kinase InhibitorsPyrazinesdifferentiation syndromeFLT3gilteritinib

Identifiers

PMID40738675
PMCPMC13019013

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.